Still SF [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2016-10-07 08:38  – Posting: # 16704
Views: 10,328

Hi VStus,

lucid words about SF and great ideas about hacking embeded Linux-machines. :-D

I think that TSDs for reference-scaling are not so important compared to ABE. Let us consider two scenarios.
  1. CV higher than expected.
    • ABE
      • In a fixed sample design we loose power.
      • In a TSD with sample size re-estimation we proceed to the second stage and preserve power.
    • RSABE or ABEL
      The acceptance range is scaled and power is maintained.
  2. CV lower than expected.
    • ABE
      • In a fixed sample design we gain power.
      • In a TSD we have some chances to demonstrate BE already in the first stage. Hence, my personal recommendation for n1 75-80% of the fixed sample’s n.
    • RSABE or ABEL
      We loose power until we reach CVwR. Then power increases.

To summarize: In reference-scaling we have to consider lower CVs only. However, the potential impact is over-rated by many. What really hurts (in all designs) is a too optimistic assumption of the GMR.

Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
20,138 posts in 4,246 threads, 1,387 registered users;
online 4 (0 registered, 4 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 22:52 UTC

The fundamental cause of trouble in the world today is
that the stupid are cocksure
while the intelligent are full of doubt.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz